These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32240735)

  • 1. The status of the terminal regions of α-synuclein in different forms of aggregates during fibrillization.
    Marvian AT; Aliakbari F; Mohammad-Beigi H; Ahmadi ZA; Mehrpooyan S; Lermyte F; Nasouti M; Collingwood JF; Otzen DE; Morshedi D
    Int J Biol Macromol; 2020 Jul; 155():543-550. PubMed ID: 32240735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The N-terminus of α-synuclein is essential for both monomeric and oligomeric interactions with membranes.
    Lorenzen N; Lemminger L; Pedersen JN; Nielsen SB; Otzen DE
    FEBS Lett; 2014 Jan; 588(3):497-502. PubMed ID: 24374342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing the dynamics of α-synuclein oligomers using hydrogen/deuterium exchange monitored by mass spectrometry.
    Mysling S; Betzer C; Jensen PH; Jorgensen TJ
    Biochemistry; 2013 Dec; 52(51):9097-103. PubMed ID: 24191706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High stability and cooperative unfolding of α-synuclein oligomers.
    Paslawski W; Andreasen M; Nielsen SB; Lorenzen N; Thomsen K; Kaspersen JD; Pedersen JS; Otzen DE
    Biochemistry; 2014 Oct; 53(39):6252-63. PubMed ID: 25216651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent α-Synuclein Aggregation Inhibitors, Identified by High-Throughput Screening, Mainly Target the Monomeric State.
    Kurnik M; Sahin C; Andersen CB; Lorenzen N; Giehm L; Mohammad-Beigi H; Jessen CM; Pedersen JS; Christiansen G; Petersen SV; Staal R; Krishnamurthy G; Pitts K; Reinhart PH; Mulder FAA; Mente S; Hirst WD; Otzen DE
    Cell Chem Biol; 2018 Nov; 25(11):1389-1402.e9. PubMed ID: 30197194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How epigallocatechin gallate binds and assembles oligomeric forms of human alpha-synuclein.
    Andersen CB; Yoshimura Y; Nielsen J; Otzen DE; Mulder FAA
    J Biol Chem; 2021; 296():100788. PubMed ID: 34019875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early stages of aggregation of engineered α-synuclein monomers and oligomers in solution.
    Li X; Dong C; Hoffmann M; Garen CR; Cortez LM; Petersen NO; Woodside MT
    Sci Rep; 2019 Feb; 9(1):1734. PubMed ID: 30741954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of the β-sheet content on the mechanical properties of aggregates during amyloid fibrillization.
    Ruggeri FS; Adamcik J; Jeong JS; Lashuel HA; Mezzenga R; Dietler G
    Angew Chem Int Ed Engl; 2015 Feb; 54(8):2462-6. PubMed ID: 25588987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SDS-induced fibrillation of alpha-synuclein: an alternative fibrillation pathway.
    Giehm L; Oliveira CL; Christiansen G; Pedersen JS; Otzen DE
    J Mol Biol; 2010 Aug; 401(1):115-33. PubMed ID: 20540950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oleuropein derivatives from olive fruit extracts reduce α-synuclein fibrillation and oligomer toxicity.
    Mohammad-Beigi H; Aliakbari F; Sahin C; Lomax C; Tawfike A; Schafer NP; Amiri-Nowdijeh A; Eskandari H; Møller IM; Hosseini-Mazinani M; Christiansen G; Ward JL; Morshedi D; Otzen DE
    J Biol Chem; 2019 Mar; 294(11):4215-4232. PubMed ID: 30655291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential of zwitterionic nanoliposomes against neurotoxic alpha-synuclein aggregates in Parkinson's Disease.
    Aliakbari F; Mohammad-Beigi H; Rezaei-Ghaleh N; Becker S; Dehghani Esmatabad F; Eslampanah Seyedi HA; Bardania H; Tayaranian Marvian A; Collingwood JF; Christiansen G; Zweckstetter M; Otzen DE; Morshedi D
    Nanoscale; 2018 May; 10(19):9174-9185. PubMed ID: 29725687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural insights into amyloid oligomers of the Parkinson disease-related protein α-synuclein.
    Gallea JI; Celej MS
    J Biol Chem; 2014 Sep; 289(39):26733-26742. PubMed ID: 25143382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structures of the E46K mutant-type α-synuclein protein and impact of E46K mutation on the structures of the wild-type α-synuclein protein.
    Wise-Scira O; Dunn A; Aloglu AK; Sakallioglu IT; Coskuner O
    ACS Chem Neurosci; 2013 Mar; 4(3):498-508. PubMed ID: 23374074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DJ-1, a Parkinson's disease related protein, aggregates under denaturing conditions and co-aggregates with α-synuclein through hydrophobic interaction.
    Zhu M; H Patel S; Han S
    Biochim Biophys Acta Gen Subj; 2017 Jul; 1861(7):1759-1769. PubMed ID: 28330770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Kinetics, Toxicity, Oligomer Formation, and Membrane Binding Capacity of α-Synuclein Familial Mutations at the A53 Site, Including the Newly Discovered A53V Mutation.
    Mohite GM; Kumar R; Panigrahi R; Navalkar A; Singh N; Datta D; Mehra S; Ray S; Gadhe LG; Das S; Singh N; Chatterjee D; Kumar A; Maji SK
    Biochemistry; 2018 Sep; 57(35):5183-5187. PubMed ID: 29771508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to increase the reproducibility of protein fibrillization in plate reader assays.
    Giehm L; Otzen DE
    Anal Biochem; 2010 May; 400(2):270-81. PubMed ID: 20149780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temperature-dependent structural changes of Parkinson's alpha-synuclein reveal the role of pre-existing oligomers in alpha-synuclein fibrillization.
    Ariesandi W; Chang CF; Chen TE; Chen YR
    PLoS One; 2013; 8(1):e53487. PubMed ID: 23349712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-existence of two different α-synuclein oligomers with different core structures determined by hydrogen/deuterium exchange mass spectrometry.
    Paslawski W; Mysling S; Thomsen K; Jørgensen TJ; Otzen DE
    Angew Chem Int Ed Engl; 2014 Jul; 53(29):7560-3. PubMed ID: 24740651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of stable α-synuclein oligomers in the molecular events underlying amyloid formation.
    Lorenzen N; Nielsen SB; Buell AK; Kaspersen JD; Arosio P; Vad BS; Paslawski W; Christiansen G; Valnickova-Hansen Z; Andreasen M; Enghild JJ; Pedersen JS; Dobson CM; Knowles TP; Otzen DE
    J Am Chem Soc; 2014 Mar; 136(10):3859-68. PubMed ID: 24527756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities.
    Alam P; Bousset L; Melki R; Otzen DE
    J Neurochem; 2019 Sep; 150(5):522-534. PubMed ID: 31254394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.